BDSI'S BIORAL DRUG DELIVERY TECHNOLOGY MAY REDUCE GI DAMAGE CAUSED BY NSAIDS AND ASPIRIN

BioDelivery Sciences International has announced that, in laboratory testing, it recently applied its licensed and patented Bioral "nanocochleate" drug delivery technology to aspirin and traditional non-steroidal anti-inflammatory drugs (NSAIDs) that are not selective Cox-2 inhibitors.

BDSI contracted with an independent testing laboratory to test its Bioral formulations of aspirin and other NSAIDs in a well-established animal model of inflammation. These proof-of-principle animal studies have demonstrated that encochleated NSAIDs enabled a statistically significant reduction in gastrointestinal toxicity compared to standard formulations at clinically relevant high doses of these NSAIDs and aspirin while providing comparable anti-inflammatory effects.